Tiny Guides, Big Impact: Focus on the Opportunities and Challenges of miR-Based Treatments for ARDS
Acute Respiratory Distress Syndrome (ARDS) is characterized by lung inflammation and increased membrane permeability, which represents the leading cause of mortality in ICUs. Mechanical ventilation strategies are at the forefront of supportive approaches for ARDS. Recently, an increasing understandi...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-02-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/25/5/2812 |
| _version_ | 1797264395772887040 |
|---|---|
| author | Chirag M. Vaswani Julia Simone Jacqueline L. Pavelick Xiao Wu Greaton W. Tan Amin M. Ektesabi Sahil Gupta James N. Tsoporis Claudia C. dos Santos |
| author_facet | Chirag M. Vaswani Julia Simone Jacqueline L. Pavelick Xiao Wu Greaton W. Tan Amin M. Ektesabi Sahil Gupta James N. Tsoporis Claudia C. dos Santos |
| author_sort | Chirag M. Vaswani |
| collection | DOAJ |
| description | Acute Respiratory Distress Syndrome (ARDS) is characterized by lung inflammation and increased membrane permeability, which represents the leading cause of mortality in ICUs. Mechanical ventilation strategies are at the forefront of supportive approaches for ARDS. Recently, an increasing understanding of RNA biology, function, and regulation, as well as the success of RNA vaccines, has spurred enthusiasm for the emergence of novel RNA-based therapeutics. The most common types of RNA seen in development are silencing (si)RNAs, antisense oligonucleotide therapy (ASO), and messenger (m)RNAs that collectively account for 80% of the RNA therapeutics pipeline. These three RNA platforms are the most mature, with approved products and demonstrated commercial success. Most recently, miRNAs have emerged as pivotal regulators of gene expression. Their dysregulation in various clinical conditions offers insights into ARDS pathogenesis and offers the innovative possibility of using microRNAs as targeted therapy. This review synthesizes the current state of the literature to contextualize the therapeutic potential of miRNA modulation. It considers the potential for miR-based therapeutics as a nuanced approach that incorporates the complexity of ARDS pathophysiology and the multifaceted nature of miRNA interactions. |
| first_indexed | 2024-04-25T00:28:14Z |
| format | Article |
| id | doaj.art-d332d7a64134437f9b85fa616e503dba |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-04-25T00:28:14Z |
| publishDate | 2024-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-d332d7a64134437f9b85fa616e503dba2024-03-12T16:46:25ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672024-02-01255281210.3390/ijms25052812Tiny Guides, Big Impact: Focus on the Opportunities and Challenges of miR-Based Treatments for ARDSChirag M. Vaswani0Julia Simone1Jacqueline L. Pavelick2Xiao Wu3Greaton W. Tan4Amin M. Ektesabi5Sahil Gupta6James N. Tsoporis7Claudia C. dos Santos8Department of Physiology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A8, CanadaDepartment of Medicine, McMaster University, Hamilton, ON L8V 5C2, CanadaInstitute of Medical Sciences, Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A8, CanadaKeenan Research Centre for Biomedical Science, St. Michael’s Hospital, University of Toronto, Toronto, ON M5B 1W8, CanadaDepartment of Physiology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A8, CanadaKeenan Research Centre for Biomedical Science, St. Michael’s Hospital, University of Toronto, Toronto, ON M5B 1W8, CanadaFaculty of Medicine, School of Medicine, The University of Queensland, Herston, QLD 4006, AustraliaKeenan Research Centre for Biomedical Science, St. Michael’s Hospital, University of Toronto, Toronto, ON M5B 1W8, CanadaDepartment of Physiology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A8, CanadaAcute Respiratory Distress Syndrome (ARDS) is characterized by lung inflammation and increased membrane permeability, which represents the leading cause of mortality in ICUs. Mechanical ventilation strategies are at the forefront of supportive approaches for ARDS. Recently, an increasing understanding of RNA biology, function, and regulation, as well as the success of RNA vaccines, has spurred enthusiasm for the emergence of novel RNA-based therapeutics. The most common types of RNA seen in development are silencing (si)RNAs, antisense oligonucleotide therapy (ASO), and messenger (m)RNAs that collectively account for 80% of the RNA therapeutics pipeline. These three RNA platforms are the most mature, with approved products and demonstrated commercial success. Most recently, miRNAs have emerged as pivotal regulators of gene expression. Their dysregulation in various clinical conditions offers insights into ARDS pathogenesis and offers the innovative possibility of using microRNAs as targeted therapy. This review synthesizes the current state of the literature to contextualize the therapeutic potential of miRNA modulation. It considers the potential for miR-based therapeutics as a nuanced approach that incorporates the complexity of ARDS pathophysiology and the multifaceted nature of miRNA interactions.https://www.mdpi.com/1422-0067/25/5/2812ARDSgene therapymiRNAnanotechnology |
| spellingShingle | Chirag M. Vaswani Julia Simone Jacqueline L. Pavelick Xiao Wu Greaton W. Tan Amin M. Ektesabi Sahil Gupta James N. Tsoporis Claudia C. dos Santos Tiny Guides, Big Impact: Focus on the Opportunities and Challenges of miR-Based Treatments for ARDS International Journal of Molecular Sciences ARDS gene therapy miRNA nanotechnology |
| title | Tiny Guides, Big Impact: Focus on the Opportunities and Challenges of miR-Based Treatments for ARDS |
| title_full | Tiny Guides, Big Impact: Focus on the Opportunities and Challenges of miR-Based Treatments for ARDS |
| title_fullStr | Tiny Guides, Big Impact: Focus on the Opportunities and Challenges of miR-Based Treatments for ARDS |
| title_full_unstemmed | Tiny Guides, Big Impact: Focus on the Opportunities and Challenges of miR-Based Treatments for ARDS |
| title_short | Tiny Guides, Big Impact: Focus on the Opportunities and Challenges of miR-Based Treatments for ARDS |
| title_sort | tiny guides big impact focus on the opportunities and challenges of mir based treatments for ards |
| topic | ARDS gene therapy miRNA nanotechnology |
| url | https://www.mdpi.com/1422-0067/25/5/2812 |
| work_keys_str_mv | AT chiragmvaswani tinyguidesbigimpactfocusontheopportunitiesandchallengesofmirbasedtreatmentsforards AT juliasimone tinyguidesbigimpactfocusontheopportunitiesandchallengesofmirbasedtreatmentsforards AT jacquelinelpavelick tinyguidesbigimpactfocusontheopportunitiesandchallengesofmirbasedtreatmentsforards AT xiaowu tinyguidesbigimpactfocusontheopportunitiesandchallengesofmirbasedtreatmentsforards AT greatonwtan tinyguidesbigimpactfocusontheopportunitiesandchallengesofmirbasedtreatmentsforards AT aminmektesabi tinyguidesbigimpactfocusontheopportunitiesandchallengesofmirbasedtreatmentsforards AT sahilgupta tinyguidesbigimpactfocusontheopportunitiesandchallengesofmirbasedtreatmentsforards AT jamesntsoporis tinyguidesbigimpactfocusontheopportunitiesandchallengesofmirbasedtreatmentsforards AT claudiacdossantos tinyguidesbigimpactfocusontheopportunitiesandchallengesofmirbasedtreatmentsforards |